Takeda Pharmaceutical Company Limited announced the acquisition of ARIAD Pharmaceuticals, Inc. on January 9th 2017, an oncology-focused biotechnology company with a portfolio of targeted therapies that is highly complementary to Takeda’s existing oncology business. Takeda will acquire all of the outstanding shares in ARIAD for $24.00 per share in cash, or an enterprise value of approximately $5.2 billion.
The acquisition of ARIAD brings two innovative targeted therapies that will transform Takeda’s existing oncology portfolio and pipeline by expanding into solid tumors and reinforcing the existing strength in hematology. Takeda’s current portfolio of hematology products is predominantly focused on multiple myeloma with Ixazomib and lymphoma with Brentuximab Vedotin. The addition of Ponatinib will broaden Takeda’s strong hematology franchise to include chronic myeloid leukemia (CML) and a subset of acute lymphoblastic leukemia (ALL). Brigatinib, an investigational drug product, has the potential to add a differentiated, global therapy in a genetically-defined subpopulation of non-small cell lung cancer (NSCLC).
Faithful to its commitment to further expand into cancer treatments, Takeda has also entered into collaboration with Maverick Therapeutics to develop Maverick’s T-cell engagement platform created specifically to improve the utility of T-cell redirection therapy for the treatment of cancer. This collaboration advances Takeda’s aspiration of curing cancer by developing innovative, targeted therapies.
The above actions are consistent with Takeda’s plan to generate growth by executing a disciplined investment strategy focused on high quality assets in the core therapeutic areas of oncology, GI and CNS. It also supports Takeda’s vision to be a top ten oncology company by 2025 and solidifies its position as a top five hematology company.
On a similar note on investments and research collaborations, previously in July 2016, Takeda has entered into an exclusive ex-U.S. license, development and commercialization agreement for Cx601, a suspension of allogeneic adipose-derived stem cells (eASC) injected intra-lesionally with TiGenix for the treatment of complex perianal fistulas in patients with Crohn’s disease. In Europe approximately one million people suffer from Crohn’s disease, with rising incidence. This collaboration and the addition of Cx601 to Takeda’s GI portfolio furthers its leadership position in GI and its commitment to patients living with Crohn’s disease.
With continuing focus on gastroenterology, Takeda made another important agreement in January 2017 around novel therapy for celiac disease. Takeda and PvP Biologics have come up with a development agreement of KumaMax, a novel enzyme designed to break down the immune-reactive parts of gluten in the stomach, thereby avoiding the painful symptoms and damage done in the small intestine from accidental gluten ingestion.
About Takeda Pharmaceutical Company
Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as our presence in Emerging Markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. For more information, visit http://www.takeda.com/news.
Takeda MCO Balkans